Day Operating Income from 2010 to 2026
| DAWN Stock | USD 11.78 0.29 2.40% |
Operating Income | First Reported 2020-03-31 | Previous Quarter -35 M | Current Value -24.3 M | Quarterly Volatility 29.4 M |
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 2.4 M or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 7.23, Dividend Yield of 0.0 or PTB Ratio of 2.23. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
Day | Operating Income | Build AI portfolio with Day Stock |
Evaluating Day One's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Day One Biopharmaceuticals's fundamental strength.
Latest Day One's Operating Income Growth Pattern
Below is the plot of the Operating Income of Day One Biopharmaceuticals over the last few years. Operating Income is the amount of profit realized from Day One Biopharmaceu operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Day One Biopharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Day One's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Day One's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Day Operating Income Regression Statistics
| Arithmetic Mean | (69,830,991) | |
| Coefficient Of Variation | (118.09) | |
| Mean Deviation | 71,212,812 | |
| Median | (14,905,000) | |
| Standard Deviation | 82,462,768 | |
| Sample Variance | 6800.1T | |
| Range | 203.5M | |
| R-Value | (0.83) | |
| Mean Square Error | 2309.5T | |
| R-Squared | 0.68 | |
| Significance | 0.000045 | |
| Slope | (13,481,916) | |
| Total Sum of Squares | 108801.7T |
Day Operating Income History
Other Fundumenentals of Day One Biopharmaceu
Day One Operating Income component correlations
Click cells to compare fundamentals
About Day One Financial Statements
Day One investors utilize fundamental indicators, such as Operating Income, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -195.5 M | -185.8 M | |
| Non Operating Income Net Other | -13.5 K | -14.2 K |
Pair Trading with Day One
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.Moving together with Day Stock
Moving against Day Stock
| 0.63 | OSE | OSE Pharma SA | PairCorr |
| 0.6 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.57 | VCYT | Veracyte Earnings Call This Week | PairCorr |
| 0.55 | DRMA | Dermata Therapeutics | PairCorr |
| 0.43 | CDIOW | Cardio Diagnostics | PairCorr |
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Day One Correlation against competitors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.